All In Biotech

Investigational drug · Phase 3

Oregovomab

Also called: MAb-B43.13

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Neoplasms.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

17

Any phase or sponsor naming "Oregovomab"

First trial start

2020

Aug 25, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Oregovomab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Peritoneal Cancer
  • Ovarian Cancer
  • Fallopian Tube Neoplasms
  • Peritoneal Carcinoma
  • Ovarian Serous Adenocarcinoma
  • Recurrent Ovarian Cancer
  • Recurrent Epithelial Cancer of Ovary
  • Recurrent Epithelial Ovarian Cancer
  • Recurrent Fallopian Tube Cancer
  • Recurrent Carcinoma of Ovary

Approved drugs for the same conditions: Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Oregovomab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 50 on PubMed

Also in development for Peritoneal Cancer

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • KAND567FractalkinePhase 21 trial

    Novakand Pharma AB · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.